2020
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]‐Fluorothymidine Positron Emission Tomography Biomarker Study
Wesolowski R, Stover D, Lustberg M, Shoben A, Zhao M, Mrozek E, Layman R, Macrae E, Duan W, Zhang J, Hall N, Wright C, Gillespie S, Berger M, Chalmers J, Carey A, Balasubramanian P, Miller B, Amaya P, Andreopoulou E, Sparano J, Shapiro C, Villalona‐Calero M, Geyer S, Chen A, Grever M, Knopp M, Ramaswamy B. Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]‐Fluorothymidine Positron Emission Tomography Biomarker Study. The Oncologist 2020, 25: e1158-e1169. PMID: 32452601, PMCID: PMC7418347, DOI: 10.1634/theoncologist.2020-0039.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerHuman epidermal growth receptor 2Advanced breast cancerPhase I studyFLT-PETBreast cancerFood and Drug AdministrationEscalating dosesPartial responseSafety profileArea under the curve 5High dosesEscalating doses of veliparibMaximum standardized uptake valueMedian progression-free survivalHormone receptor (HR)-positiveFanconi anemiaFLT-PET scansPhase II doseRP2D of veliparibDose-limiting toxicityProgression-free survivalEarly response assessmentStandardized uptake valueMonitoring therapy response
2015
Loss of antigenicity with tissue age in breast cancer
Combs SE, Han G, Mani N, Beruti S, Nerenberg M, Rimm DL. Loss of antigenicity with tissue age in breast cancer. Laboratory Investigation 2015, 96: 264-269. PMID: 26568292, DOI: 10.1038/labinvest.2015.138.Peer-Reviewed Original ResearchConceptsHuman epidermal growth receptor 2Estrogen receptorQuantitative immunofluorescenceProtein expressionSeries of formalinRandom-effects modelHuman breast carcinomaLarge cooperative groupsParaffin-embedded tissuesKi67 expressionBreast carcinomaBreast cancerIndividual patientsTissue microarrayClinical investigationClinical questionsReceptor 2Tumor specimensPositive casesLoss of antigenicityFFPE biospecimensQuantitative protein expressionBiomarkersCooperative groupsPreservation time
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply